GLP-1 receptor agonist toxicity: Difference between revisions
No edit summary |
|||
| Line 15: | Line 15: | ||
==Management== | ==Management== | ||
*Symptomatic management | |||
**Anti-nausa medications (e.g., [[zofran]]) | |||
*Consider stopping other glucose-lowering (i.e, diabetic) medications | |||
==Disposition== | ==Disposition== | ||
Revision as of 20:17, 31 January 2024
Background
- GLP-1 receptor agonists (e.g., semaglutide) are injectable medication used for diabetes management and weight loss
- Poison control centers have reported increasing inquiries related to possible overdoses
Clinical Features
Differential Diagnosis
Evaluation
Workup
Diagnosis
Management
- Symptomatic management
- Anti-nausa medications (e.g., zofran)
- Consider stopping other glucose-lowering (i.e, diabetic) medications